The device, intended to counteract the effects of an opioid overdose, costs $4,500 for a pack of two. In 2014, a two-pack cost only $690, according to the report.
More than 30 U.S. senators on Wednesday sent a letter to Kaléo criticizing the device’s high list price and asking for more information on the company’s pricing strategies.
“Such a steep rise in the cost of this drug threatens to price-out families and communities that depend on naloxone to save lives,” the senators wrote in the letter. Many of the senators represent states deeply affected by the ongoing opioid epidemic.
Kaléo argues its patient assistance efforts, including large patient discounts and few out-of-pocket costs, justify the list prices for its products, reports Fortune.
More articles on supply chain:
Supply chain tip of the week: 9 questions to test your inventory management IQ
10 statistics on drug, device recalls in Q4
6 quotes from Pfizer CEO on Trump, drug prices and more
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
